Solara Active Pharma Sciences Limited (NSE:SOLARA) held a board meeting on July 23, 2026, and approved the unaudited financial results for the quarter ended June 30, 2026. The board also reviewed the Limited Review Report issued by statutory auditor Deloitte Haskins & Sells. The announcement was filed with the BSE and NSE under SEBI Listing Regulations 30 and 33.
Key Highlights
- The board of directors approved unaudited standalone and consolidated financial results for Q1 FY27, ended June 30, 2026, on July 23, 2026.
- M/s. Deloitte Haskins & Sells, the company's statutory auditor, issued a Limited Review Report on the results.
- The board meeting commenced at 12:00 P.M. and concluded at 01:05 P.M. on July 23, 2026.
- Unaudited financial results are available on the company's investor relations portal at https://solara.co.in/investor-relations/financial-information.
- The filing was submitted under Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
About the Company
Solara Active Pharma Sciences Limited (NSE:SOLARA, BSE:541540) is a pharmaceutical company engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs) and pharmaceutical formulations. The company operates manufacturing facilities and has a presence across multiple geographies. Incorporated on September 20, 2017, Solara is listed on both the National Stock Exchange and BSE Limited. The company's corporate office is located at TICEL Bio Park, 6th Floor, Module No. 601, 602, 603, Phase II, CSIR Road, Taramani, Chennai, Tamil Nadu 600113. The company's registered office is at 9th Floor, Cyber One, Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai 400703.
Announcement in Detail
The Board of Directors of Solara Active Pharma Sciences Limited met on July 23, 2026, to review and approve the company's quarterly financial performance. During the meeting, the board considered and approved the unaudited financial results on both a standalone and consolidated basis for the quarter ended June 30, 2026. The results were accompanied by a Limited Review Report from M/s. Deloitte Haskins & Sells, the company's chartered accountant and statutory auditor.
The board meeting was held in accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the filing of financial results and board outcome has been submitted to both the BSE Limited and NSE. The specific financial figures, performance metrics, and other quantitative details are enclosed with the filing and are available on the company's investor relations website. The board concluded its deliberations at 01:05 P.M. after commencing at 12:00 P.M.
Impact on Investors
The approval and disclosure of Q1 FY27 unaudited financial results represent the company's routine quarterly reporting obligation to shareholders and market regulators. Investors will note that the financial results are unaudited and have been subject to a Limited Review by the statutory auditor, which provides a lower level of assurance than a full audit. The results are now in the public domain and available for investor review and analysis on the company's investor relations portal.
The filing triggers the start of the quarter's disclosure cycle under SEBI Listing Regulations. Investors should review the complete financial statements, including the Limited Review Report, notes to accounts, and any footnote disclosures, to assess the company's operational and financial performance. The unaudited results will later be finalized in the audited annual results for FY27 at year-end, at which point any material variances can be identified and explained by management.
Sector / Market Context
India's pharmaceutical sector, which includes active pharmaceutical ingredient (API) manufacturers, continues to be a significant component of the country's healthcare and export economy. API manufacturers supply pharmaceutical companies globally and domestically with key raw materials for drug formulation. The sector has been characterized by competitive pricing, regulatory compliance requirements, and the need for continuous investment in manufacturing infrastructure and quality assurance. Quarterly reporting cycles and timely disclosure of financial results are integral to regulatory compliance and investor confidence in listed pharma companies.